Aquestive Therapeutics Ownership
| AQST Stock | USD 3.21 0.10 3.22% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 91 M | Current Value 87 M | Avarage Shares Outstanding 44.8 M | Quarterly Volatility 22.3 M |
Aquestive |
Aquestive Stock Ownership Analysis
About 48.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.51. Aquestive Therapeutics had not issued any dividends in recent years. Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey. Aquestive Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 157 people. For more info on Aquestive Therapeutics please contact Keith Kendall at 908 941 1900 or go to https://www.aquestive.com.Besides selling stocks to institutional investors, Aquestive Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Aquestive Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Aquestive Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Aquestive Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Aquestive Therapeutics Insider Trades History
About 5.0% of Aquestive Therapeutics are currently held by insiders. Unlike Aquestive Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Aquestive Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Aquestive Therapeutics' insider trades
Aquestive Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aquestive Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aquestive Therapeutics backward and forwards among themselves. Aquestive Therapeutics' institutional investor refers to the entity that pools money to purchase Aquestive Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 736.9 K | Bank Of America Corp | 2024-12-31 | 690.3 K | Essex Investment Management Company, Llc | 2024-12-31 | 623.3 K | Northern Trust Corp | 2024-12-31 | 599.8 K | Pale Fire Capital Se | 2024-12-31 | 525.8 K | Bracebridge Capital, Llc | 2024-12-31 | 459.2 K | Ubs Group Ag | 2024-12-31 | 420.6 K | Woodline Partners Lp | 2024-12-31 | 409.3 K | Stifel Financial Corp | 2024-12-31 | 398.6 K | Bratton Capital Management, L.p. | 2024-12-31 | 9.8 M | Blackrock Inc | 2024-12-31 | 6 M |
Aquestive Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aquestive Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aquestive Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aquestive Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aquestive Therapeutics Outstanding Bonds
Aquestive Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Aquestive Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Aquestive bonds can be classified according to their maturity, which is the date when Aquestive Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Aquestive Therapeutics Corporate Filings
F4 | 11th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 10th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
| 24th of January 2025 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aquestive Stock Analysis
When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.